Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soquelitinib vs SOC in R/R PTCL-NOS, FHTCLs, or sALCL
NCT06561048Phase 3Recruiting
- Sponsor
- Corvus Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of soquelitinib in peripheral T-cell lymphoma (PTCL), Follicular T-cell lymphoma (FTCL), systemic anaplastic large cell lymphoma (sALCL), sponsored by Corvus Pharmaceuticals. Started Oct 2024; status: recruiting.
02
Drugs
soquelitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)Follicular T-cell lymphoma (FTCL)systemic anaplastic large cell lymphoma (sALCL)
Beyond the preview
Go deeper on NCT06561048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561048.